demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
lenzilumab LIVE-AIR ...

0 studies excluded by filtering options 0